01/16/2023 Number of shares and voting rights of ADOCIA as of December 31st, 2022 Icon check
01/12/2023 ADOCIA Announces its financial calendar for 2023 Icon check
01/12/2023 A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab., 2023;25(5):1241-1248. Icon check
12/29/2022 ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao Icon check
12/21/2022 ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023 Icon check
12/15/2022 Number of shares and voting rights of ADOCIA as of November 30th, 2022 Icon check
12/01/2022 Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products Icon check
11/16/2022 Number of shares and voting rights of ADOCIA as of October 31st, 2022 Icon check
10/25/2022 ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates Icon check
10/13/2022 Number of shares and voting rights of ADOCIA as of September 30th, 2022 Icon check
10/06/2022 ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis Icon check
10/03/2022 ADOCIA: Upcoming investor meetings Icon check
Investors Webinar of Sept 20th, 2022
09/19/2022 ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update Icon check
09/15/2022 ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th Icon check
09/14/2022 Number of shares and voting rights of ADOCIA as of August 31st, 2022 Icon check
09/07/2022 ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes Icon check
2022 AdoShell Islets Presentation
08/25/2022 Number of shares and voting rights of ADOCIA as of July 31st, 2022 Icon check
08/24/2022 ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update Icon check
07/11/2022 Number of shares and voting rights of ADOCIA as of June 30th, 2022 Icon check
06/23/2022 Adocia publishes its Letter to Shareholders Icon check
06/23/2022 ADOCIA – Letter to Shareholders – June 2022 Icon check
06/21/2022 ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes Icon check
06/14/2022 Number of shares and voting rights of ADOCIA as of May 31st, 2022 Icon check
05/20/2022 ADOCIA Announces its annual Shareholders’ meeting to be held on June 28, 2022 in Paris Icon check
05/18/2022 ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update Icon check
05/18/2022 ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao Icon check
05/13/2022 Number of shares and voting rights of ADOCIA as of April 30th, 2022 Icon check
05/09/2022 ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao Icon check
04/25/2022 ADOCIA Announces the Release of its Universal Registration Document for the Year 2021 Icon check
04/19/2022 ADOCIA announces its annual results for 2021 and presents an update on activities Icon check
04/15/2022 Number of shares and voting rights of ADOCIA as of March 31st, 2022 Icon check
04/11/2022 ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao Icon check
03/28/2022 Adocia strengthens its cash position by 19 million euros following a real estate transaction Icon check
03/16/2022 Number of shares and voting rights of ADOCIA as of February 28th, 2022 Icon check
02/23/2022 ADOCIA announces 2021 fourth quarter financial results Icon check
02/15/2022 Number of shares and voting rights of ADOCIA as of January 31st, 2021 Icon check
01/11/2022 Number of shares and voting rights of ADOCIA as of December 31st, 2021 Icon check
01/06/2022 ADOCIA announces its financial calendar for 2022 Icon check
12/20/2021 ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2022 Icon check
12/15/2021 Number of shares and voting rights of ADOCIA as of November 30th, 2021 Icon check
12/13/2021 Adocia Files Patent for Technology to Enable Oral Drug Delivery of Peptides Icon check
11/19/2021 Number of shares and voting rights of ADOCIA as of October 31st, 2021 Icon check
10/26/2021 Adocia announces 2021 third quarter financial results and a financing of €7 million Icon check
10/14/2021 ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China Icon check
10/12/2021 Number of shares and voting rights of ADOCIA as of September 30th, 2021 Icon check
09/21/2021 ADOCIA announces Oral Presentation Reviewing M1Pram (ADO09) at the occasion of the 57th Annual Meeting of EASD Icon check
09/13/2021 Number of shares and voting rights of ADOCIA as of August 31st, 2021 Icon check
09/10/2021 Adocia To Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Icon check
09/07/2021 ADOCIA Announces First Half 2021 Financial Results and Provides an Update on Activities Icon check
08/23/2021 Number of shares and voting rights of ADOCIA as of July 31st, 2021 Icon check
07/29/2021 Bilan Semestriel du contrat de liquidité Adocia conclu avec la société Kepler Capital Markets
07/22/2021 ADOCIA Announces Second Quarter 2021 Financial Results Icon check
07/15/2021 Number of shares and voting rights of ADOCIA as of June 30th, 2021 Icon check
06/29/2021 ADOCIA Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes Icon check
06/27/2021 ADO09, a coformulation of insulin A21G and pramlintide (Pram), improves blood glucose control and reduces body weight in subjects with T1D, Dr. Grégory Meiffren, June 27, 2021, ADA virtual event.
06/15/2021 ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions Icon check
06/10/2021 Number of shares and voting rights of ADOCIA as of May 31st, 2021 Icon check
06/08/2021 ADOCIA confirms its eligibility for the PEA–PME Icon check
Join our mailing list. Subscribe